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Background: The African Surgical Outcomes Study (ASOS) showed that surgical patients in Africa have a mortality twice the global 
average. The working hypothesis is that patients die as a result of failure to rescue following complications in the postoperative 
period. The African Surgical OutcomeS-2 (ASOS-2) Trial plans to test the efficacy of increased postoperative surveillance in high risk 
patients for decreasing perioperative morbidity and mortality. This pilot trial aimed i) to evaluate the adequacy of data produced 
by the data collection strategies of the ASOS-2 Trial, ii) to evaluate the fidelity of implementation of the increased postoperative 
surveillance intervention, and iii) to understand the acceptability, appropriateness and feasibility of the intervention and the trial 
processes. 
Methods: The ASOS-2 Pilot Trial was a mixed-methods (quantitative-qualitative) implementation study focusing on the 
intervention arm of the proposed ASOS-2 Trial. The intervention is increased postoperative surveillance for high-risk surgical 
patients. The intervention protocol was implemented at all sites for a seven-day period. A post pilot trial survey was used to collect 
data on the implementation outcomes.
Results: 803 patients were recruited from 16 hospitals in eight African countries. The sampling and data collection strategies 
provided 98% complete data collection. Seventy-three percent of respondents believed that they truly provided increased 
postoperative surveillance to high risk patients. In reality 83/125 (66%) of high-risk patients received some form of increased 
postoperative surveillance. However, the individual components of the increased postoperative surveillance intervention were 
implemented in less than 50% of high-risk patients (excepting increasing nursing observations). The components most frequently 
unavailable were the ability to provide care in a higher care ward (32.1%) and assigning the patient to a bed in view of the nurses’ 
station (28.4%). Failure to comply with available components of the intervention ranged from 27.5% to 54.3%. The post pilot survey 
had a response rate of 30/40 (75%). In Likert scale questions about acceptability, appropriateness, and feasibility of the ASOS-2 
intervention, 63% to 87% of respondents indicated agreement. Respondents reported barriers related to resources, trial processes, 
teamwork and communication as reasons for disagreement.
Conclusions: The proposed ASOS-2 Trial appears to be appropriate, acceptable and feasible in Africa. This pilot trial provides 
support for the proposed ASOS-2 Trial. It emphasises the need for establishing trial site teams which address the needs of all 
stakeholders during the trial. A concerted effort must be made to help participating hospitals to increase compliance with all the 
components of the proposed intervention of ‘increased postoperative surveillance’ during the ASOS-2 Trial.
Keywords: Trial, cluster randomised, Trial, pilot, Implementation science, Mixed methods, Mortality, Surgery
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Introduction
The African Surgical Outcomes Study (ASOS)1 was designed to 
provide robust surgical outcomes data from Africa, to inform 
the Commission on Global Surgery.2 ASOS showed that surgical 
patients in Africa were generally young, and of a low surgical 
risk, yet, when compared to the global average, they were twice 
as likely to die following surgery.1 It is possible that the increase 
in mortality was predominantly secondary to failure to rescue, 
which is death following complications.1 ASOS suggested that 
limited surgical resources, in terms of personnel and facilities, 
compromise provision of a safe postoperative environment for 
surgical patients in Africa. 
The limited variation in postoperative morbidity and mortality 
across the countries in ASOS,1 suggests that a continent-wide 
strategy to provide safer postoperative care may decrease 
surgical mortality in Africa. With limited resources available 
for postoperative care, a strategy is needed that focuses care 
on the patients at greatest risk of severe complications and 
death. Identifying high-risk patients and instituting increased 
postoperative surveillance selectively for these patients may 
decrease failure to rescue, and hence decrease mortality. 
This is the strategy which has been adopted for the African 
Surgical OutcomeS-2 (ASOS-2) Trial; a cluster randomised trial 
to determine whether increased postoperative surveillance of 
adult African surgical patients reduces postoperative mortality.3
The objectives of the ASOS-2 Pilot Trial were: i) to evaluate 
the adequacy of data produced by the sampling and data 
collection strategies of the ASOS-2 Trial, ii) to evaluate the 
fidelity of implementation of the trial intervention, and iii) to 
understand the acceptability, appropriateness and feasibility of 
the intervention and the trial processes. 
Methods
This pilot study is presented in accordance with the CONSORT 
recommendations for randomised pilot and feasibility trials.4 
Trial design
The proposed ASOS-2 Trial is a pragmatic trial. It is an 
international cluster randomised controlled trial in African 
countries. Participating surgical sites will be randomised to either 
the intervention arm of increased postoperative surveillance or 
the control arm of usual postoperative care. All consecutive adult 
patients aged 18 years and over admitted to participating sites 
undergoing elective and non-elective surgery are to be included 
in the trial. Sites which have been randomised to the intervention 
arm will need to provide increased postoperative surveillance to 
those surgical patients with a risk score of ≥ 10 according to the 
ASOS Surgical Risk Calculator. The ASOS Surgical Risk Calculator 
was developed from the first ASOS data and recently published 
elsewhere.5 The primary outcome of the ASOS-2 Trial is in-
hospital mortality, censored at 30 days. 
The ASOS-2 Pilot Trial was a mixed-methods (quantitative-
qualitative) implementation study evaluating the intervention 
arm of the proposed ASOS-2 Trial. For the pilot trial the 
intervention protocol was implemented at all sites for a seven-
day period at which time data collection was stopped. Data was 
collected by means of a case report form (CRF) and an electronic 
post-pilot survey (Appendices 1 and 2). The CRF documented the 
necessary data to measure: i) completeness of trial data and ii) 
fidelity of implementation of the intervention. The survey was 
used to collect additional data on the implementation outcomes 
(fidelity, acceptability, appropriateness and feasibility). The 
survey contained two sections: i) the study intervention 
(increased postoperative surveillance guided by the risk 
calculator), and ii) the trial processes. The types of questions 
used were a combination of Likert scale and open questions. The 
ASOS-2 Pilot Trial was not registered on a trial registry.
Participants
Eligible participants included all consecutive adult patients aged 
18 years and over admitted to participating sites undergoing 
elective and non-elective surgery. Pilot sites were selected based 
on readiness to participate. Only sites with full local ethical 
approval could participate in the pilot. The initial ethics approval 
was from the Human Research and Ethics Committee of the 
University of Cape Town (HREC 081/2018). The trial has a waiver 
of individual consent, and operated on a broadcast consent 
model, where participating sites broadcast their involvement in 
the trial by means of publicly visible posters. 
The post-pilot survey was conducted on the REDCap platform6 
and distributed via email to named investigators one week after 
the pilot project. Survey responses were anonymous.
Interventions
All eligible surgical patients were screened with the ASOS 
Surgical Risk Calculator.5 Patients scoring 10 or more points, 
were considered high-risk, as they have a predicted incidence 
of severe complications and death above the average for 
the ASOS cohort.5 The protocol required that these patients 
receive increased postoperative surveillance which included 
the following components: i) admission to a higher care ward 
than had been planned prior to risk stratification, ii) an increase 
in the frequency of postoperative nursing observations, iii) 
ensuring that the patient is placed in view of the nursing station, 
and not in a remote location in the ward, or iv) allowing family 
members to stay with the patient in the ward. The care givers 
were encouraged to provide as many of the components of the 
intervention, for as long as possible to the high-risk patients. A 
bedside clinical guidance poster was provided for all high-risk 
patients with information on the leading causes of postoperative 
mortality in African surgical patients as documented in ASOS; 
these were surgical site infections, bloodstream infection and 
acute respiratory distress syndrome, pneumonia, acute kidney 
injury, postoperative bleeding, and cardiac arrest.1 A WhatsApp 
messaging programme was integrated into the REDCap data 
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collection tool. The WhatsApp programme provided automated 
responsive data collection reminders to support clinician 
registration and to improve data integrity and completeness.
Outcomes
The effectiveness outcomes (mortality and severe complications) 
of the ASOS-2 Trial were not captured during the ASOS-2 Pilot 
Trial, as data collection was stopped at seven days and the pilot 
was not powered to measure these outcomes. Based on our 
previous ASOS experience, we are confident that we can capture 
these data during the full trial.1
The implementation outcomes of the pilot were: i) percentage 
completeness of data produced by the sampling and data 
collection strategies, ii) fidelity of implementation of the 
trial intervention, and iii) acceptability, appropriateness and 
feasibility of the intervention and the trial processes. 
Fidelity was defined as individual patient level exposure to 
increased surveillance, measured quantitatively with the CRF. 
It assessed the number of surveillance methods a patient 
was exposed to, the duration of days for which each of these 
were implemented, and the perceived ease or difficulty of 
implementation. Acceptability, appropriateness and feasibility 
were measured qualitatively and semi-quantitatively (by Likert 
scale) at the individual investigator level by means of a post-pilot 
investigator survey. Acceptability was defined as stakeholder 
comfort with the content and complexity of the intervention 
they are asked to implement. Appropriateness was defined 
as stakeholder belief about necessity and a goodness of fit of 
the intervention for their hospital. Feasibility was defined as 
stakeholder opinion regarding utility and sustainability of the 
intervention at their hospital. No changes were made to the 
pilot trial assessments or measurements after the pilot trial 
commenced.
Theoretical framework
The post-pilot survey was built around the implementation 
outcomes proposed by Proctor7 and operationalised using 
selected questions from the Consolidated Framework for 
Implementation Research (CFIR) interview guide tool.8 
Essentially the outcome of the ASOS-2 trial depends not only on 
whether increased postoperative surveillance truly decreases 
postoperative mortality and morbidity, but also the degree to 
which increased postoperative surveillance can be implemented 
in a real-world setting. The CFIR framework addresses elements 
of the intervention, the context and the process as drivers of 
fidelity of implementation. Although the questions in the post-
pilot survey were modelled around an established framework, 
they have not been validated in this setting, and for this reason 
the survey employed a mixed-methods approach. 
The pilot trial was conducted to inform changes to the proposed 
protocol to ensure the success of the ASOS-2 Trial, as such there 
were no prespecified criteria used to judge whether to proceed 
with a future definitive trial. 
Sample size
There was no proposed sample size for the pilot trial. The sample 
represents the maximum number of trial centres that were 
willing to participate and had full ethical approval at the date 
determined for the pilot trial. There were no stopping rules for 
the pilot trial, as the trial was to run for one week, and there 
would be insufficient time to determine any indication for 
stopping. The survey sampling strategy aimed to avoid duplicate 
responses by sending a link to the electronic survey to individual 
named investigators. 
All pilot sites were in the intervention arm, hence there was no 
randomisation, or need for allocation concealment. There was no 
blinding in the pilot trial. 
Implementation
All patients who had surgery from Monday to Friday of the 
recruitment week, were risk stratified using the ASOS Surgical 
Risk Calculator at the time of surgery by the anaesthetist.5 Any 
patient with a score of 10 or more, was considered high-risk, and 
would require increased postoperative surveillance. The pilot 
trial ran for one week from 7 am on the Monday, to 6.59 am on 
the following Monday. Both the intervention and the patient 
follow-up finished at the end of the pilot week.  
Statistical analysis
Quantitative analyses. When appropriate, categorical variables 
were compared using Fisher’s exact test. Likert scale responses 
were treated as ordinal data and summarised using proportions 
(n/N [%]). Continuous variables were tested and confirmed for 
normality, summarised using mean and standard deviation, 
and compared using unpaired t-tests, as all data was normally 
distributed. 
Qualitative analyses.  Free text responses to open questions 
were analysed through an iterative process by two investigators 
to identify common codes and code categories. LDT and BMB 
independently coded the data with a constructivist approach; 
no codes or code categories were specified up front. Following 
independent coding of all responses, LDT and BMB agreed on 
a final coding method and worked together to collapse codes 
to the minimum number of codes that remained representative 
of all responses. Finally, the data structure was extracted to a 
coding matrix and narrative summaries prepared around the 
themes in the matrix. 
Statistical analyses were performed using the Statistical Package 
for the Social Sciences (SPSS) version 24 (SPSS Inc., Chicago, IL, 
USA) and R statistical software package version 3.4 (R Foundation 
for Statistical Computing, Austria).  Qualitative data analysis was 
done in RQDA: R-based Qualitative Data Analysis. R package 
version 0.3-1 (2018). http://rqda.r-forge.r-project.org/  
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Results
Participants
803 patients were recruited in the ASOS-2 Pilot Trial, from 16 
hospitals in eight countries; Benin (5%), Democratic Republic of 
the Congo (< 1%), Kenya (3%), Mali (4%), Mauritius (9%), Niger 
(6%), Nigeria (4%), and South Africa (68%). These hospitals 
included one district hospital (contributing 14% of participants), 
six secondary hospitals (contributing 20% of participants), and 
nine tertiary hospitals (contributing 66% of participants). Seven 
hospitals provided eligible patient screening data, of which six 
entered data on 98.5% of eligible patients into the database. The 
seventh hospital provided patient data on 146/195 (74.9%) of all 
patients eligible for the pilot trial. 
The patient recruitment in the ASOS-2 Pilot Trial is shown in Figure 
1. Less than 2% of the patients were not risk stratified using the 
ASOS Surgical Risk Calculator. The proportion of agreement with 
patient risk stratification was 96.7% with the ASOS Surgical Risk 
Calculator score (κ=0.88). 125/772 (16.2%) were risk stratified 
as high-risk patients based on an ASOS Surgical Risk Calculator 
score of 10 or more. The mean (standard deviation) ASOS Surgical 
Risk Calculator score was 5 ( 3) for the not high-risk patients, and 
13 (3) for the high-risk patients. 
Recruitment
Each pilot site selected a single recruitment week between 
September and November 2018. 
Patient characteristics 
The patients’ characteristics are shown in Table 1. Most of the 
patients had a good physical status classification, with 649/772 
(84.1%) being American Society of Anesthesiologists (ASA) 
category 1 or 2. More than half of the surgical procedures were 
urgent or emergent, and over 2/3 were classified as being of 
intermediate or major severity. Over a 1/3 of all operations were 
obstetric procedures.
The fidelity of the ‘increased postoperative surveillance’ 
intervention
The proportion of patients who received increased postoperative 
surveillance is shown in Table 2. Two-thirds of patients classified 
as high-risk received increased postoperative surveillance. 
Of the four components comprising increased postoperative 
surveillance, only increased nursing observations were used in 
more than 50% of patients. The median duration of increased 
postoperative surveillance was two days for all components, 
with the exception of utilisation of a higher care ward which was 
0 days. The postoperative surveillance bedside guide was placed 
at the patient’s bedside in 48% of cases.
Figure 1. African Surgical OutcomeS-2 (ASOS-2) Pilot Trial flow diagram of patient recruitment
803 patients included in ASOS-2 Pilot Trial
High-risk patients who received ‘increased postoperative surveillance’
83/125 (66.4%)
Patients not logged at time of pilot trial analysis
17/803 (2.1%)
Patients with missing ASOS Surgical Risk 
Calculator Score
14/786 (1.8%)
High-risk patients who did not receive ‘increased 
postoperative surveillance’
42/125 (33.6%)
Patients with ASOS Surgical Risk Calculator Score
772/786 (98.2%) with 125/772 (16.2%) high-risk patients
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The ease and difficulty of providing the individual components 
of increased postoperative surveillance are shown in Table 3. 
The components of increased postoperative surveillance most 
frequently unavailable were the ability to provide care in a higher 
care ward (32%) and assigning the patient to a bed in view of the 
nurses’ station (28%). When provided, the easiest components to 
implement were assigning the patient to a bed in view of the 
nurses’ station (39%) or having the family with the patient in the 
ward (39%). A failure to comply with the available components 
of the intervention (not done) ranged from 28% to 54%.
The post ASOS-2 Pilot Trial survey
The post-pilot survey had a response rate of 30/40 (75%). Of the 
respondents, 15 were anaesthesia providers, 14 were surgery 
providers, and one was a nurse. Likert responses to questions 
Table 1. Description of patient cohort and associated ‘increased postoperative surveillance’
All patients (n=786)
Patients with ‘increased 
postoperative surveillance’ 
(n=125)




Age (years) 39.0 (16.4) 46.3 (18.7) 38.6 (16.2) <0.001
Female 508/765 (66.4%) 45/121 (37.2%) 463/644 (71.9%)
Male 257/765 (33.6%) 76/121 (62.8%) 181/644 (28.1%) <0.001
ASA category
1 289/772 (37.4%) 23/125 (18.4%) 266/647 (41.1%) <0.001
2 360/772 (46.6%) 37/125 (29.6%) 323/647 (49.9%)
3 116/772 (15.0%) 58/125 (46.4%) 58/647 (9.0%)
4 and 5 7/772 (0.1%) 7/125 (5.5%) 0/647 (0.0%)
Grade of surgery
Minor 184/772 (23.8%) 7/125 (5.6%) 177/647 (27.4%) <0.001
Intermediate 468/772 (60.6%) 66/125 (52.8%) 402/647 (62.1%)
Major 120/772 (15.5%) 52/125 (41.6%) 68/647 (10.5%)
Urgency of surgery
Elective 356/772 (46.1%) 29/125 (23.2%) 327/647 (50.5%) <0.001
Urgent 230/772 (29.8%) 57/125 (45.6%) 173/647 (26.7%)
Emergency 186/772 (24.1%) 39/125 (31.2%) 147/647 (22.7%)
Surgical speciality
Orthopaedic 138/772 (17.9%) 15/125 (12.0%) 123/647 (19.0%) 0.073
Plastics or Breast 28/772 (3.6%) 3/125 (2.4%) 25/647 (3.9%) 0.423
Obstetrics 273/772 (35.4%) 3/125 (2.4%) 270/647 (41.7%) <0.001
Gynaecology 74/772 (9.6%) 1/125 (0.8%) 73/647 (11.3%) <0.001
Gastro-intestinal or Hepatobiliary 102/772 (13.2%) 56/125 (44.8%) 46/647 (7.1%) <0.001
Urology 52/772 (6.7%) 8/125 (6.4%) 44/647 (6.8%) 1.0
Cardiothoracic/Vascular 20/772 (2.6%) 14/125 (11.2%) 6/647 (0.9%) <0.001
Nar, nose and throat 17/772 (2.2%) 3/125 (2.4%) 14/647 (2.2%) 0.869
Neurosurgery 17/772 (2.2%) 14/125 (11.2%) 3/647 (0.5%) <0.001
Other 51/772 (6.6%) 8/125 (6.4%) 43/647 (6.6%) 1.0
Indication for surgery
Non-communicable disease 328/772 (42.5%) 52/125 (41.6%) 276/647 (42.7%) 0.844
Infection 83/772 (10.8%) 43/125 (34.4%) 40/647 (6.2%) <0.001
Trauma 105/772 (13.6%) 29/125 (23.2%) 76/647 (11.7%) 0.001
Caesarean section 256/772 (33.2%) 1/125 (0.8%) 255/647 (39.4%) <0.001
Preoperative comorbidity
Hypertension 157/763 (20.6%) 44/121 (36.4%) 113/642 (17.6%) <0.001
COPD/Asthma 69/761 (9.1%) 16/121 (13.2%) 53/640 (8.3%) 0.086
HIV positive/AIDS 84/761 (11.0%) 5/121 (4.1%) 79/640 (12.3%) 0.007
Data are mean (SD) or n (proportion). Odds ratios (unadjusted) were constructed for in-hospital severe complications and death with univariable 
binary logistic regression analysis. The denominator for each group is shown. ASA=American Society of Anesthesiologists. GIT= gastrointestinal. 
COPD=chronic obstructive pulmonary disease. HIV=human immunodeficiency virus. AIDS=acquired immunodeficiency syndrome.
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about acceptability, appropriateness, fidelity, and feasibility of 
the intervention is shown in Table 4, the trial processes in Table 
5, and qualitative responses in Supplementary Table 1. 
In response to Likert scale questions about acceptability of 
the various components of the intervention, 63% to 84% of 
respondents rated the components acceptable, except for 
family presence at the bedside, which only 37% of respondents 
rated as acceptable. In the qualitative feedback, most 
respondents (17/25 [68%]) reported that the intervention is 
acceptable and will improve quality of care. Reasons for not 
accepting the intervention were related to scarce personnel and 
physical resources, obstructive hospital policies and practices, 
a misunderstanding of the risk calculator, and inadequate 
communication with stakeholders. 
In response to Likert scale questions, 70% to 87% of respondents 
rated the intervention as appropriate. Only 15 (50%) of 
respondents answered the open question about relative 
advantage of the intervention. Their responses were balanced 
(seven positive versus eight negative). Respondents typically 
reported personnel constraints and need for education of 
frontline staff as barriers to implementation. Some of the 
responses suggested either the question or the intervention was 
misunderstood. In both instances improved communication 
with stakeholders was indicated.
In response to Likert scale questions, 69% to 79% of respondents 
rated the ASOS-2 intervention as feasible. 20/30 [67%] of 
respondents answered the open question about resource 
readiness. They listed bed capacity, structural limitations (ward 
layout), personnel shortage, a need for monitoring equipment 
and financial constraints as barriers to implementation. 
Respondents also listed barriers not related to resources 
(hospital policies and nursing management approval).
In response to the Likert scale question, 73% of the respondents 
believed that they truly provided ‘increased postoperative 
surveillance’. The fidelity as measured by the CRF showed 
that 83/125 (66%) of high-risk patients received some form of 
increased postoperative surveillance.  
Responses to the Likert scale questions on trial processes 
included 13 respondents who received WhatsApp messages 
during the pilot. Their responses varied. 85% found the messages 
useful and would like to receive the message support during the 
full trial. However, in response to a question about goodness 
of fit, only 4/13 (31%) of respondents thought the WhatsApp 
messages were a good fit. Seven respondents answered the 
open question about the WhatsApp messages, their responses 
address the distribution of WhatsApp communication, the 
nature of messages and the potential burden of receiving too 
many messages.
In response to Likert questions about stakeholder involvement 
and leadership, 64% to 76% of respondents indicated agreement 
with the trial processes. The qualitative responses suggested that 
the full range of stakeholders, from family and frontline staff, to 
heads of departments (HODs) and hospital management need 
engagement in the implementation process. 
The respondents generally agreed that the CRF was acceptable. 
Respondents were less decisive about the REDCap data 
capturing system, 5/11 (45%) agreed it was ‘straightforward’, 
while 4/11 (36%) remained undecided. 
80% of the respondents believe that they have the capacity to 
do ASOS network projects annually. 
The qualitative questions were structured to elicit information 
on specific aspects of implementation, however, many of the 
responses overlapped between the questions. The central 
themes that were identified in the responses are presented in 
the coding matrix (Supplemental Table 1). These themes can 
be summarised as a need for improved communication with 
stakeholders, development of site investigator teams, managing 
the concern of limited resource capacity, and streamlining the 
trial process. 
No adverse events related to the trial were reported.
Discussion
Statement of principal findings
The ASOS-2 Pilot Trial had three objectives. With respect to the 
first objective, the pilot trial suggested that the data produced 
by the sampling and data collection strategies was good with 
almost 98% complete data collection for the pilot. The data 
was sufficiently pragmatic to describe the cohort, allow risk 
stratification, and characterise the intervention adequately. The 
Table 2. Description of the ‘increased postoperative surveillance’ provided to ‘high-risk’ patients
n/N (%, 95% CI)
Proportion of high-risk patients in the sample 125/772 (16.2%, 13.6-18.8)
Proportion of high-risk patients that received ‘increased postoperative surveillance’ 83/125 (66.4%, 58.1-74.7)
Intervention Proportion [n/N(%)] Days (median, IQR)
Higher care ward 38/125 (30.4%) 0 days (0-2)
Increased nursing observations 75/125 (60.0%) 2 days (1-4)
Assigned a bed in view of nurses’ station 51/125 (40.8%) 2 days (0-3)
Family with patient in ward 42/125 (33.6%) 2 days (0-4)
‘Postoperative surveillance bedside guide’ at the patient’s bedside? 60/125 (48.0%) 2 days (0-5)
CI confidence interval; IQR interquartile range
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cohort description supports data adequacy since the patients 
and the procedures correspond with those recorded in the first 
ASOS study.   
The second objective was to evaluate the fidelity of 
implementation of the trial intervention. The pilot trial suggests 
that the ASOS Surgical Risk Calculator5 is easy to use to identify 
the high-risk patient. The individual components of the 
intervention were implemented in less than 50% of high-risk 
patients (with the exception of increasing nursing observations) 
(Table 2). The compliance with the intervention may therefore be 
considered poor, especially as the individual components could 
have been increased by between 28% and 54% in the current 
cohort, and most respondents considered the components 
of the intervention ‘easy’ to implement with the exception 
of placement in a higher care ward (Table 3). An important 
observation is that despite our assessment of the compliance 
with the intervention being poor, the respondents believed that 
they had indeed provided ‘increased postoperative surveillance’ 
to the ‘high-risk’ patients (Table 4).
The third objective was to understand the acceptability, 
appropriateness and feasibility of the intervention. The pilot 
suggests that the proposed ASOS-2 Trial is acceptable, appropriate 
and feasible. The majority of the qualitative responses were very 
supportive of the proposed intervention (Supplementary Table 
1). The only component of the intervention which the median 
respondent considered unacceptable was having the patient’s 
family at the bedside. The qualitative responses suggested 
that this was multifactorial; which included staffing attitudes, 
hospital policy, security, and ward space. The trial intervention 
was generally considered acceptable. Involving stakeholders was 
considered simple by the investigators. However, the hospital 
which provided data on only 75% of all eligible patients screened, 
had particular difficulty establishing a pilot trial hospital team. 
The qualitative data clearly identifies that the stakeholders in the 
trial cover the broad range of hospital management, surgeons, 
anaesthetists, nursing staff, and other frontline ward staff. 
The trial processes suggest that the negative score for Caesarean 
section on the ASOS Surgical Risk Calculator, creates the 
impression that obstetrics is not considered as a serious risk 
factor. Occasional disagreement between clinical impression of 
a patient and the ASOS Surgical Risk Calculator was mentioned. 
The WhatsApp messaging was found to be useful, although 
there was no consensus on the appropriate number of messages, 
or the composition of the WhatsApp hospital site investigator 
group. Some concerns were raised about the data capturing 
process, specifically the need to return to the data base multiple 
times for data capture on the same patient. 
Limitations 
The pilot trial has poor representation from district hospitals. 
Furthermore, the pilot did not assess the main trial outcomes, 
although we are confident in the ability of the investigators 
to capture these data, as they are similar to those successfully 
collected across Africa in ASOS.1 It is possible that the duration 
of the components of the intervention may be under-reported, 
as the pilot trial stopped on the Monday, which is only the third 
postoperative day for ‘high-risk’ patients recruited on the Friday 
into the trial. Acceptable definitions for data completeness 
and fidelity were not prespecified. This shortcoming will be 
addressed in the main trial. The pilot survey respondents are 
not representative of all the key individuals identified in the 
survey. The anonymous nature of the survey means that we did 
not collect data regarding the respondents’ country or hospital. 
Therefore, we cannot distinguish differences in responses at a 
country or hospital level. 
Generalisability
The pilot trial methods and findings may be generalisable to the 
definitive trial due to: i) completeness of the data collection, and ii) 
the consistency in the survey responses regarding acceptability, 
appropriateness, and feasibility in the survey, despite data from 
hospitals across eight African countries. Importantly, there was 
overwhelming support for the appropriateness of the proposed 
intervention in the qualitative assessment. 








Higher care ward 36/112 (32.1) 40/112 (35.7) 23/112 (20.5) 13/112 (11.6)
Increased nursing observations* 20/135 (14.8) 43/135 (31.8) 29/135 (21.5) 43/135 (31.9)
Assigned a bed in view of nurses’ 
station
31/109 (28.4) 30/109 (27.5) 6/109 (5.5) 42/109 (38.5)
Family with patient in ward 3/94 (3.2) 51/94 (54.3) 3/94 (3.2) 37/94 (39.4)
‘Postoperative surveillance bedside 
guide’ at the patient’s bedside?
3/110 (2.7) 51/110 (46.4) 11/110 (10.0) 45/110 (40.9)
*Denominator >125 due to high-risk patients both receiving and not receiving the intervention on different days 
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Interpretation 
We believe that the pilot trial was successful, as it has provided 
valuable information on all three of its objectives. These data 
have important implications for progression from the pilot to the 
future definitive trial.
To improve fidelity we must secure: i) a representative local trial 
team with accepted leadership structure at each hospital, ii) buy-
in to a shared vision by all key individuals, iii) define adequacy 
of increased surveillance, iv) improve education and training 
on implementation of the intervention, and v) identify agreed 
workarounds for barriers to implementation that are specific to 
the sites (e.g. address problems with ward layout, bed allocation 
and family visitation policies). These goals can be achieved by 
involving a broader range of stakeholders in the local trial team, 
increasing contact time with site investigators during the build-
up to the trial, increasing education during site enrolment and 
initiation, and providing a roll-in period for the site to test the 
protocol and establish acceptable workarounds prior to the 
ASOS-2 Trial.
Although the ASOS Surgical Risk Calculator was simple to use 
for risk stratification in the pilot trial, it is necessary to educate 
investigators in the principles related to i) the derivation of 
the calculator (and hence the individual point scores), ii) the 
expected outcomes associated with a score above the cut for 
high-risk in the trial, immaterial of the clinical impression, and 
iii) the expected number of patients that will require increased 
surveillance per day. 
The WhatsApp groups may need to be individualised according 
to local needs at each site. Moreover, it would be desirable to 
simplify the patient data capture portal. We believe this will 
be possible in the definitive trial, when the questions around 
‘fidelity’ of implementation which were specific to the pilot trial 
will be removed.
Exposure to the individual components of the proposed 
intervention was suboptimal. A key focus of education during 
site initiation will be on ensuring that each component of the 
intervention is maximally applied during the trial. A concern that 
needs to be addressed, is the current perception that increased 
postoperative surveillance was done, even though there was 
substantial room for improvement in delivering the intervention. 
The recurring concern about resource constraints is a reality of 
the setting; it should be clarified that the goal of the intervention 
is not to increase workload for frontline staff, but rather to 
redistribute resources to those at higher risk of complication. 
Conclusion
Morbidity and mortality following surgery in Africa is significantly 
worse than the global average. These poor outcomes appear to 
be consistent across many African countries, a phenomenon 
which is possibly driven by ‘failure to rescue’.1 The proposed 
‘increased postoperative surveillance’ intervention for the ASOS-2 
Trial appears to be appropriate, acceptable and feasible in Africa. 
This pilot trial provides substantial support for the proposed trial. 
It emphasises the need to establish site teams that address the 
needs of all stakeholders, the need to help stakeholders identify 
ways to work around site specific barriers to implementation, 
and finally, the need to pursue increased compliance with all 
the components of the proposed intervention of ‘increased 
postoperative surveillance’.
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Appendix 
Members of the African Surgical OutcomeS-2 
(ASOS-2) Pilot Trial
ASOS-2 Pilot Trial Steering Committee: 
B M Biccard, L Du Toit, P Forget, HL Kluyts, R M Pearse.
ASOS-2 Pilot Trial Investigators: Benin. National Leader: E 
Zoumenou
Centre Hospitalier Universitaire départemental de l’Ouémé et du 
Plateau (CHUD/OP): Ahounou Ernest.
Democratic Republic of Congo. National Leader: 
Munlemvo DM
El Rapha Clinic:  T Likongo.
University Hospital of Kinshasa: T Djoho, AKM Kilembe, SHN 
Nehema.
Kenya. National Leaders: AKN Ndonga, ZWW Ngumi
Mater Misericordiae Hospital: AKN Ndonga.
Mali. National Leader: Sanogo Zimogo
CHU du Point G: BD Boubacar, B Moussa, S Zimogo Zié.
Hôpital de Gao: S Souleymane.
Mauritius. National Leader: V Gobin
Dr AG Jeetoo Hospital: MRA Aboobakar, NF Fokeerah, VMK 
Kissoon, RR Ramsewak.
Jawaharlall Nehru Hospital: SJ Joomye.
Niger. National Leader:  Chaibou M Sani
Centre Hospitalier Regional: FD Djibo.
National hospital de Zinder: AH Harissou.
Nigeria. National Leader: Akinyinka O Omigbodun, Simbo 
D Amanor-Boadu
Aminu Kano Teaching Hospital, Kano: SA Aji, LJC Anyanwu, M 
Atiku, A Attah, AB Muhammad, RO Oseni, M Salisu-Kabara.
South Africa. National Leader: H-L Kluyts
Dr George Mukhari Academic Hospital:  BJ Baloyi-Mnisi, MZ Koto, 
ME Mabitsela, T Mabotja, B Mthelebofu, SR Ndlovu.
Nelson Mandela Academic Hospital:  B Mrara, AO Usenbo.
New Somerset Hospital:  M Nock, AR Reed, H Steinhaus, NJ 
Vickery
Tygerberg Hospital: RC Pillay.
Worcester hospital: PJ Buckle, PJ Jansen van Vuuren, CM Keen, TA 
Killingbeck, SJ Kim, N Swanepoel, C van der Westhuizen, HA van 
Zyl, MM Venter, PJ Viljoen. 
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ASOS-2 unique patient ID       
  
Patient name: ___________________________________          DOB      
Patient hospital number : _________________________                         ASOS-2 Pilot Trial CRF 
          
m m d d y y y y 
Age   years (<30 points; 0 points/ 30-69 years; 1 point/ ≥70 years; 3 points) Sex    M      F    
ASA    I (0 points)      II (2 points)     III  (5 points)    IV (8 points)     V (8 points)   
Chronic co-morbid disease (tick all that apply):   Hypertension      HIV / AIDS        Diabetes mellitus       COPD / Asthma 
Surgical procedure category (select single most appropriate):        Gynaecology (minus 1 point)        Obstetrics (minus 1 point)    
  Orthopaedic (0 points)      Ear, nose and throat (3 points)      Plastics or breast  (1 point)            Urology  (2 points)                  
Neurosurgery(4 points)  Gastro-intestinal or Hepato-biliary(3 points)   Cardiothoracic/ vascular(3 points)  Other(0 points) 
Indication for surgery:  
  Non-communicable disease  (0 points)    Caesarean section (minus 2 points)    Trauma (1 point)      Infection (2 points)     
Urgency of surgery:       Elective (0 points)   Urgent (3 points)   Emergency (4 points) 
Severity of surgery:       Minor (0 points)   Intermediate (2 points)   Major (4 points) 
Start of surgery time (24h) & date:  :                  
ASOS Surgical Risk Score points per risk factor: 
Age + ASA + Surgical procedure category + Indication for surgery + Urgency surgery + Severity surgery =   points 
Time that the ASOS Surgical Risk Score was calculated:   Pre-op       Intra-op     Immediately post-op 
Predicted ASOS Risk Score:  Not high-risk patient (<10 points)     High-risk patient (≥10 points) 
 
Not high-risk patient: (Complete postoperative care given):Higher care ward No  Yes Increased nursing observations No Yes   
Assigned a bed in view of nurses’ station   No   Yes     Family with patient in ward  No   Yes       
 High-risk patient:  
(Complete all postop surveillance)  
Day 0 Day 1 Day 2 Day 3 Day 4+ Intervention 
Any no Any yes 
Higher care ward No  Yes     No  Yes No  Yes No  Yes No  Yes       
Increased nursing observations No  Yes     No  Yes No  Yes No  Yes No  Yes       
Assigned a bed in view of nurses’ station No  Yes            No  Yes            No  Yes No  Yes No  Yes       
Family with patient in ward No  Yes            No  Yes            No  Yes No  Yes No  Yes       
‘Postoperative surveillance bedside 
guide’ at the patient’s bedside? 




Severe complications (tick all that apply):   Superficial or deep surgical site, or body cavity infection   Y     N   Postop day  
Bloodstream infection or ARDS   Y     N    Postop day  Pneumonia              Y     N   Postop day  
Urinary tract or AKI    Y     N    Postop day  Postoperative bleed              Y     N   Postop day  
Cardiac arrest    Y     N    Postop day  Other severe complication          Y     N   Postop day  
Critical care admission to treat postoperative complications:  No   Yes Postop day        Days in hospital after surgery  
Status at hospital discharge or 30th postoperative in-hospital day:  Alive & discharged     Alive & still in hospital     Dead 




d  0 1 2 
Postoperative Follow Up 
 
Appendix 1. ASOS-2 Pilot Trial case record form (CRF)
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ASOS-2 unique patient ID       
  
Patient name: ___________________________________          DOB      
Patient hospital number : _________________________                         ASOS-2 Pilot Trial CRF 
          
m m d d y y y y 
Definition of ‘Indication for surgery’: This is the underlying initiating disease/ event which ultimately resulted in the need for surgery. High care ward: A 
postoperative ward which is dedicated to providing increased postoperative care, when compared to the normal postoperative surgical ward. A high care 
ward can include an intensive care ward. Increased frequency of nursing observations: Nursing observations which are conducted more frequently, than 
the normal frequency of observations on the postoperative ward. Patient bed close to nurses’ station: The patient is positioned in a bed close to the 
nursing station to ensure that the nurses can always see the patient from the nursing station. Family members to stay with the patient in the ward: If the 
family members are asked to stay with the patient on the ward, because of a concern that the patient is at increased risk of death of morbidity in the 
postoperative period. Number of paces from bed to nurses’ station:  The number of paces of the shortest distance from the end of the patient’s bed to the 
nurses’ station.  
Definition of a ‘Severe Complication’: Results in significant prolongation of hospital stay and/or permanent functional limitation or death. Almost always 
requires clinical treatment. Surgical site infection (superficial): Infection involving only superficial surgical incision which meets the following criteria: i) 
Infection occurs within 30 days after surgery and ii) Involves only skin and subcutaneous tissues of the incision and iii) The patient has at least one of the 
following: a) purulent drainage from the superficial incision, or b) organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision and at least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat, or superficial 
incision is deliberately opened by surgeon and is culture positive or not cultured. A culture-negative finding does not meet this criterion, or c) diagnosis of a 
incisional surgical site infection by a surgeon or attending physician Surgical site infection (deep): An infection which involves both superficial and deep 
parts of surgical incision and meets the following criteria: i) Infection occurs within 30 days after surgery if no surgical implant is left in place or one year if 
an implant is in place and ii) The infection appears to be related to the surgical procedure and involves deep soft tissues of the incision (e.g. fascial and 
muscle layers) and iii) The patient has at least one of the following: a) purulent drainage from the deep incision but not from the organ/space component of 
the surgical site, or b) a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive or no cultures were taken whilst 
the patient has at least one of the following signs or symptoms of infection: fever (>38°C) or localized pain or tenderness. A culture-negative finding does 
not meet this criterion, or c) an abscess or other evidence of infection involving the deep incision is found on direct examination, during surgery, or by 
histopathologic or radiologic examination, or d) diagnosis of a deep incisional surgical site infection by a surgeon or attending physician. Surgical site 
infection (organ/space): An infection which involves any part of the body excluding the fascia or muscle layers and meets the following criteria: i) Infection 
occurs within 30 days after surgery and ii) The infection appears to be related to the surgical procedure and involves any part of the body, excluding the skin 
incision, fascia, or muscle layers, that is opened or manipulated during the operative procedure and iii) The patient has at least one of the following: a) 
purulent drainage from a drain that is placed through a stab wound into the organ/space, b) organisms isolated from an aseptically obtained culture of fluid 
or tissue in the organ/ space , or c) an abscess or other, or d) evidence of infection involving the organ/space that is found on direct examination, during 
reoperation, or by histopathologic or radiologic examination, or e) diagnosis of an organ/space surgical site infection by a surgeon or attending physician. 
Bloodstream infection: An infection which is not related to infection at another site and which meets at least one of the following criteria: i) Patient has a 
recognised pathogen cultured from blood cultures which is not related to an infection at another site, ii) Patient has at least one of the following signs or 
symptoms: fever (>38°C), chills, or hypotension and at least one of the following: a) common skin contaminant cultured from two or more blood cultures 
drawn on separate occasions, or b) common skin contaminant cultured from at least one blood culture from a patient with an intravascular line, and a 
physician starts antimicrobial therapy, or c) positive blood antigen test. Acute Respiratory Distress Syndrome (ARDS): Respiratory failure, or new or 
worsening respiratory symptoms, commencing within one week of surgery; and a chest radiograph or computed tomography scan which demonstrates 
bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; and respiratory failure not fully explained by cardiac failure or fluid 
overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic oedema if no risk factor is present. Severity grading: Severe: 
PaO2:FiO2 ≤100 mmHg with PEEP ≥5 cmH2O. Guidance: If altitude is higher than 1000 m, a correction factor should be calculated as follows: (PaO2:FiO2 x 
[barometric pressure/760 mmHg]). PEEP, positive end-expiratory pressure; CPAP, non-invasive continuous positive airways pressure. Pneumonia: Chest 
radiographs with new or progressive and persistent infiltrates, or consolidation, or cavitation, and at least one of the following: i) fever (>38°C) with no 
other recognized cause, or ii) leucopaenia (<4,000 white blood cells/mm3) or leucocytosis (>12,000 white blood cells/mm3), or iii) for adults >70 years old, 
altered mental status with no other recognised cause; and at least two of the following: a) new onset of purulent sputum or change in character of sputum, 
or increased respiratory secretions, or increased suctioning requirements, or b) new onset or worsening cough, or dyspnoea, or tachypnoea, or c) rales or 
bronchial breath sounds, d) worsening gas exchange (hypoxaemia, increased oxygen requirement or increased ventilator demand). Guidance: Two 
radiographs are required for patients with underlying pulmonary or cardiac disease. The definition may be used to identify ventilator associated pneumonia. 
Urinary tract infection: An infection associated with at least one of the following signs or symptoms which should be identified within a 24 hour period; 
fever (>38 °C), urgency, frequency, dysuria, suprapubic tenderness, costovertebral angle pain or tenderness with no other recognised cause, and a positive 
urine culture of ≥105 colony forming units/mL with no more than two species of microorganisms. Acute Kidney Injury (AKI): Serum creatinine Increase of 
3.0 times baseline within 7 days or increase in serum creatinine to ≥4.0 mg/dL (≥354 μmol/L) with an acute rise of >0.5 mg/dL (>44 μmol/L) or initiation of 
renal replacement therapy, or urine output ≤0.3 ml/kg/h for 24 hours or anuria for 12 hours Guidance: Baseline serum creatinine must be measured before 
surgery but an estimated value can be used if the patient does not have chronic kidney disease. Postoperative haemorrhage: Blood loss occurring within 72 
hours after the end of surgery which would normally result in transfusion of blood. Cardiac arrest: The cessation of cardiac mechanical activity, as 
confirmed by the absence of signs of circulation. ECG changes may corroborate the incidence of cardiac arrest. Other severe complications: If any of the 
following complications result in a significant prolongation of hospital stay and/or permanent functional limitation or death, then mark ‘Other severe 
complication’ as ‘Yes’. Note that they will almost always requires clinical treatment. Critical care admission to treat postoperative complications: 
Postoperative complications requiring admission to critical care to treat the postoperative complications or provide critical care support necessitated by the 
severity of the postoperative complications.  
Days in hospital after surgery: Total number of days in hospital after surgery. Status at hospital discharge or 30th postoperative in-hospital day: The 
survival status of the patient at hospital discharge, or at the 30 in-hospital day (if the patient had not yet been discharged following surgery). The study is 
censored at the 30th in hospital postoperative day.  
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ASOS-2 unique patient ID       
  
Patient name: ___________________________________          DOB      
Patient hospital number : _________________________                         ASOS-2 Pilot Trial CRF 
          
m m d d y y y y 
 
 
Guidance for use of paper case record form (CRF) 
Remove this page before use in data collection 
 
1. This CRF is provided in a format which can be edited.  
2. Baseline data will often be readily available to anaesthetists during surgery whilst follow-up data on 
complications may be most easily collected by surgeons. 
3. Investigators should write the patient name and date of birth on the CRF. When you enter the data on 
the internet based CRF you will receive an ASOS-2 patient ID. Please write this on the paper CRF as 
well in case we need to contact you to check your data. 
4. Please take care to enter the date clearly and correctly. Mistakes are common data describing time 
and date. 
The page number in the footer is not for bibliographic referencingwww.tandfonline.com 29
The African Surgical OutcomeS-2 (ASOS-2) Pilot Trial, a mixed-methods implementation study 
Appendix 2. An implementation survey for the 
ASOS-2 pilot trial
Dear ASOS-2 Pilot Trial Investigators 
ASOS-2 Pilot Trial Survey
Informed consent
Dear Colleagues
1. Purpose of survey: To understand your experience of the 
ASOS-2 Pilot Trial, in order to help us improve the protocol 
for the main ASOS-2 Trial.
2. Why were you chosen to participate? You have been chosen 
to participate, as you were an investigator in the ASOS-2 
Pilot Trial. 
3. Length of participation: This is a simple survey which 
should take about 15 minutes to complete.
4. Is your identity and information safe? Your personal 
information will be kept confidential and identity will be 
kept anonymous. We will be using codes and the only 
people who will be aware of these codes are the lead 
investigator (Bruce Biccard) and the REDCap Administrator 
(Dawid van Straaten).
5. Can I change my mind and withdraw from the survey? 
Participation in the survey is voluntary. By participating in 
this survey, you are consenting to participate. Should you 
wish to withdraw from the survey, you are welcome to do 
so with no consequences.
6. Feedback: We will provide feedback on the survey to all 
participants. 
7. If I have any queries or problems, who can I get in touch 
with?
Contact Details for questions relating to the survey:
Professor Bruce Biccard 
Department of Anaesthesia and Perioperative Medicine 
D23 Groote Schuur Hospital 
Faculty of Health Sciences 
University of Cape Town 
Email: bruce.biccard@uct.ac.za
The survey
The survey takes the form of two sections; i) The first section 
contains questions that relate specifically to the ASOS-2 Pilot 
Trial intervention i.e. the actual act of providing ‘increasing 
postoperative surveillance’, and ii) The second section includes 
questions on the trial processes e.g. getting ethics approval, 
completing the CRF, working with REDCap etc. 
SECTION A: Providing ‘increasing postoperative 
surveillance’
Definitions
• “Stakeholders”” include: Nurses, clinicians and hospital 
management
• “Intervention”: The action of providing ‘increased 
postoperative surveillance’. The “content” of the intervention 
are the four options for intervention, i.e. i) higher care ward, ii) 
increased frequency of nurses’ observations, iii) the patient’s 
bed in view of the nurses’ station and iv) having the family at 
patient’s bedside.
Please see Table 1.
Likert Scale: 1. Strongly disagree, 2. Disagree, 3. Neutral, 4. Agree, 
5. Strongly agree
SECTION B: The ASOS-2 Trial processes
Please see Table 2. 
Added questions;
1. I received too many WhatsApp reminders during the ASOS-2 
Pilot Trial.
2. I received too many e-mails during the ASOS-2 Pilot Trial.
1. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: 
conceptual distinctions, measurement challenges, and research agenda. 
Administration and Policy in Mental Health and Mental Health Services Research 
2011; 38: 65-76.
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Table 1. Definitions 
Conceptual definitions Operational definitions Variable definitions
Acceptability
Stakeholder level attitude towards 
acceptability of the intervention
Are stakeholders comfortable with 
the content and complexity of 
the intervention they are asked to 
implement?
1. [Ordinal] The four components (i.e. higher care ward, increased postop 
surveillance etc.) of the ASOS-2 intervention are acceptable for my 
hospital. 5-point Likert scale.  
2. [Ordinal] The complexity of the ASOS-2 intervention is acceptable 
i.e. it was simple to implement). 5-point Likert scale (CFIR* Intervention 
characteristic – complexity)
3. [Ordinal] The ASOS-2 intervention was well received in our 
organization. 5-point Likert scale (CFIR* Inner setting – climate) 
4. [Qualitative] What did the stakeholders at your hospital think of the 
intervention? (CFIR* Intervention characteristic – strength of evidence)
Appropriateness
Stakeholder  level  bel ief 
regarding appropriateness of the 
intervention
Do stakeholders believe the 
intervention is necessary and a 
good fit for their hospital?
5. [Ordinal] I believe that the ASOS-2 intervention is a good fit for my 
hospital. 5-point Likert scale.
6. [Ordinal] The ASOS-2 intervention is essential in providing appropriate 
care for ‘high-risk’ surgical patients at my hospital. 5-point Likert scale. 
(CFIR* Inner setting – tension for change)
7. [Ordinal] The intervention fits well with existing work processes and 
practices within our setting. 5-point Likert scale. (CFIR* Inner setting – 
compatibility)
8. [Ordinal] Compared to other possible programmes, the main ASOS-2 
Trial will have a high priority in my work. 5-point Likert scale. (CFIR* Inner 
setting – relative priority)
9. [Qualitative] Are there other interventions that you think would be 
more appropriate to implement in order to prevent severe postoperative 
complications and deaths? (CFIR* Intervention characteristic – relative 
advantage)
Feasibility
Stakeholder level opinion about 
the experience of the intervention 
in their institution 
Do stakeholders think the 
intervention is useful and 
sustainable at their hospital?
10. [Ordinal] The ASOS-2 intervention was useful at my hospital. 5-point 
Likert scale.  
11. [Qualitative] Did you have sufficient resources to implement 
and administer at least two of the four components of the ASOS-2 
intervention? If, no, what resources are needed to make this intervention 
possible at your hospital? (CFIR* Readiness – available resources) 
12. [Ordinal] It is likely that I will be able to continue the intervention at 
my hospital if it shows benefit in the main ASOS-2 Trial. 5-point Likert 
scale. (CFIR* Individual characteristics – beliefs) 
13. [Ordinal] The important key leaders and managers at my hospital 
were involved in the ASOS-2 Pilot Trial. 5-point Likert scale. (CFIR* 
Readiness – leadership involvement)
14. [Qualitative] Going forward, who are the key influential individuals 
at your hospital who need to be involved with the implementation of 
the ASOS-2 intervention? What is their position in the hospital? (CFIR* 
Process – engaging) 
Fidelity
Stakeholder belief regarding 
adherence; integrity; and quality 
of program delivery
Do stakeholders believe the 
ASOS-2 inter vention was 
implemented successfully at their 
hospital? 
15. [Ordinal] I believe that the ‘high-risk’ patients truly received ‘increased 
postoperative surveillance’ compared to the care that they would 
normally have been given. 5-point Likert scale. 
16.  [Qualitative] What is needed to ensure that patients truly receive 
‘increased postoperative surveillance’?
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Table 2. The ASOS-2 Trial processes
Whatsapp
Stakeholder opinion regarding 
utility of the intervention
Are stakeholders of the opinion 
the Whatsapp message system 
facilitated the pilot trial process?
17. [Ordinal] The ASOS-2 Pilot Trial would have been more difficult 
without the Whatsapp messaging support. 5-point Likert scale. (CFIR* 
Inner setting – tension for change)
18. [Ordinal] The Whatsapp messaging fits well with the running 
of the ASOS-2 Pilot Trial.  5-point Likert scale. (CFIR* Inner setting – 
compatibility)
19. [Qualitative] What features would improve the use of the Whatsapp 
messaging in the ASOS-2 Trial?
Site initiation
Stakeholder opinion about the 
way their site participated in the 
pilot trial
Do stakeholders think their correct 
people were involved in running 
the pilot trial at their hospital?
20. [Ordinal] It was a simple process to involve the key leaders and 
stakeholder at my hospital in running the ASOS-2 pilot. 5-point Likert 
scale.  
21. [Ordinal] We had a clear plan on how to involve the various key 
leaders and stakeholders at my hospital. 5-point Likert scale.  
22. [Ordinal] It was easy to delegate the tasks involved in running the 
ASOS-2 Pilot Trial amongst the stakeholders at my hospital. 5-point Likert 
scale.  
23. [Qualitative] What changes to the trial processes will make the main 
ASOS-2 Trial run smoother at your hospital? 
Data collection
Stakeholder attitude towards the 
processes involved in collecting 
pilot data
Do stakeholders think the CRF, 
screening form and REDCap tools 
were easy to use and appropriate 
for the pilot trial? 
24. [Ordinal] The case report form (CRF) was easy to follow. 5-point Likert 
scale.
25. [Ordinal] The documentation with video guidance was helpful for 
understanding the CRF. 5-point Likert scale.
26. [Ordinal] The CRF manages to capture the important information 
without being too long. 5-point Likert scale.
27. [[Ordinal] Capturing the data onto REDCap was straightforward. 
5-point Likert scale.
28. [Ordinal] We developed a simple way of keeping track of all eligible 
cases at my hospital. 5-point Likert scale.
29. [Qualitative] What improvements would you make to the CRF, 
screening record and REDCap database to make the work easier for the 
main ASOS-2 Trial?
Trial participation
Stakeholder  att i tude to 
sustainable involvement in ASOS 
projects
Do stakeholders feel they can 
maintain the level of involvement 
that was required during the pilot 
in annual future projects? 
30. [Ordinal] I/we have the capacity at the hospital to maintain my/our 
involvement with similar ASOS projects about once a year. 5-point Likert 
scale.
*CFIR is the Consolidated Framework for Implementation Research. https://cfirguide.org/
